Compare Amphastar Pharmaceuticals Inc (AMPH) vs Bumble Inc (BMBL) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Bumble (BMBL) trades at $2.83, down 0.53% with bearish technical signals. The company reported mixed Q2 2026 results, beating earnings estimates but missing on revenue with declining paying users. Despite a gross margin of 72.84%, Bumble shows negative profitability metrics with -57.96% net margin and -87.65% ROE. Recent news indicates strategic shifts toward IRL events and AI matchmaking amid exploration of potential sale options.

Outlook remains challenging with significant execution risks. While valuation multiples appear attractive (P/S 0.39, P/B 0.72), persistent user declines and negative cash flow create headwinds. Analyst consensus leans Hold (73.91%) with $3.62 price target suggesting 28% upside, but success hinges on product transformation reversing user trends.